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Recent discussions regarding global access to
innovations in health in developing countries
have focused on intellectual property rights
(IPR).1 For example, IPR are embedded at
each stage of vaccine development and access,
including research (laboratory and clinical
programs), appropriate regulations to ensure
safety and efficacy, manufacturing capabilities
to meet international quality standards,
licensing and international procurement.2
Indeed, although not the sole factor affecting
access, IPR nevertheless are ubiquitous and
important.3 Management of IPR can be
advanced via dynamic linkages, for example,
public–private partnerships such as the
International AIDS Vaccine Initiative.4 Hence,
IPR can be an impediment (restricting access)
or an opportunity (creating linkages)
depending on how they are managed.
Johanna Gibson’s Intellectual Property, Medicine
and Health: Current Debates is an ambitious
attempt to bridge the gap between IPR
(largely patents) and the ethical, moral and
philosophical issues which should influence
global access to innovations in health.
This intent is noteworthy and timely, as the
complexities are important to address and there
is an urgent need for clear-headed strategy.
However, disappointingly, the book largely

fails, as it is a rambling polemic that lacks focus,
clarity and originality. Wading through the
thicket of verbiage becomes so daunting that
whatever message might be present is lost. The
book also is flawed in its skewed interpretation
of IP law and lack of forward vision. As such,
it mostly stands as a rehashing of previous
material, adding little in the way of new
analyses or suggested strategic options.
The 223-page book is divided into four
sections: (1) Health: the life of health, the
health of intellectual property; (2) Rights: the
human right to health, health development
and culture, patent morality; (3) Life: the
technology of life, life’s libraries; (4) Access:
access, use. Each of these sections then
expands on the topic; for example ‘rights’ are
further discussed as the right to selfdetermination, right to access to medicine
and the right to benefit from one’s creativity.
The author then juxtaposes these rights
with IPR, drawing conclusions and making
inferences about developing countries’ access
to innovations in health that might be true
under certain circumstances, yet are largely
skewed toward the presumed injustice of the
global system of IPR, that is, how the North
has weaponized IPR to further dominate the
South. The author’s citing of notoriously
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anti-IPR organizations, for example,
RAFI (p. 129) and Greenpeace (p. 107),
as authoritative, credible sources, further
exacerbates this advocacy.
The book’s messages are often lost
in a densely entangled mass of nearly
incomprehensible prose. In addition, there
is an annoying overuse of jargon (for example,
‘arguably’ and ‘articulated’), as if the spoken
word had been directly dictated to text, with
little or no independent editorial oversight in
later drafts of the manuscript (assuming there
actually were later drafts). Verbosity abounds, for
example: ‘In other words, in place is a strict
division between the material and objective
nature of the intellectual property system with
the subjectivity of moral rights rendered
peripheral to the organic unity of that system.
Thus, the social and legitimate agency of the
actors within that system is deferred by the
priority attached to the economic modeling of
innovation and creativity’ (p. 11). Wordiness
is further coagulated by throat-clearing slang:
‘Significantly, a cultural interrogation of the
patent system precipitates recognition of the
critical value of access to the intention of the
system. Arguably, this access value is articulated
through the concept of use within the patent
framework’ (p. 22) (italic emphasis added by
reviewer). For subsequent works, it might
be advisable to consult Strunk and White for
guidance on concise writing.5
Confusing legal discussion also appears. For
example: ‘Therefore, although it is beyond the
remit of an economic system of regulation to
fulfill the ethical oversight of these fields of
technology, the patent system features in the
moral dilemma of biotechnology inventions.
Arguably, although often described to the
contrary, it is not the ownership as such but the
authorship that is the critical antagonist in these
debates’ (p. 13) (italic emphasis added by
reviewer). Patents have inventors, not authors.
Authors are for copyrighted works, for
example, books. This is the same legally
operative terminology in both US and UK
patent law as well as the European Patent
Office.
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Another example further illustrates
the confused tone of the legal discussion:
‘The market is achieved by imposing certain
monopoly rights with respect to use, thus
achieving an artificial scarcity on certain
manifestations ( fixations) of information’ (p. 24)
(italic emphasis added by reviewer). There
are two problems with this statement. First,
patents are not monopolies per se. Patents
neither automatically confer market
domination nor establish a cartel. To assert
that patents confer monopolistic power defies
logic, as they protect inventions that are,
by definition, new and hence cannot be
‘scarce’ as they are novel in the first instance.
Patents simply confer property rights, albeit
intangible. As per McCarthy: ‘Without a
rigorous analysis and definition of the relevant
economic market, one cannot say that the
claims of all, or even many, patents define a
substantial portion of a true relevant market’.6
Puzzlingly, the book also has a section
(p. 188) that addresses patent pools, and
again uses the term ‘monopoly’ (‘Therefore,
a patent pool can also create a monopoly
over certain technology if competitors
cooperate …’), yet fails to distinguish that
use of the term from its ubiquitous (mis)use
throughout the book. The second problem
with the statement above is, once again,
the confusion of copyright with patent
terminology: ‘fixations of information’ are
copyrighted (inventions are patented).
On page 115, US5567607 is incorrectly
cited as the original patent on the Harvard
Oncomouse. US5567607, a patent covering
a method for producing transgenic animals,
is assigned to Incel, was granted in 1996
and is not connected via patent prosecution
(nor even citation) to the original Oncomouse
patent. The issue is further confused by the
assertion that this method would cover the
mice themselves (presumably as compositions
of matter), which is wrong: it would only
cover the method. However, the error is truly
glaring in that the correct original patent
for Oncomice is US4736866 (inventors are
Leder and Stewart; assignee is Harvard),

© 2010 Macmillan Publishers Ltd. 1462-8732 J our n a l of C om m er c i a l B i ot ec h n ol ogy

Vol. 16, 2, 191–193

Book Review

which claims the transgenic animal as the
invention.7 Such poor research casts an
overall shadow across the credibility of
this book, and suggests that this was an
early draft improperly accelerated into
publication.
This book intimates that the industrialized
North uses IPR to subjugate the developing
South. However, it fails to consider that
problems will continue until the South
acquires the capacity and capability to assert
its own interests, agendas and rights. Topics
covered in the book should therefore be
analyzed in the context of developing
countries’ stages of development, infrastructure,
public health systems and technological
sophistication. This can be a win-win scenario:
wealth creates wealth, and rich trading partners
create economic synergy.8 Recent examples
of rapidly developing economies support this,
including India, China and Brazil. Sadly,
this concept of development is only briefly
mentioned on page 136: ‘The opportunity
to license with developing-country partners
is recognized not only as a mechanism by
which to avoid delays or failure to market
but also as an important contribution to local
innovation and development’. Similarly, the
author mentions the Bonn Guidelines for
the Convention on Biological Diversity (p. 76)
but fails to suggest that the establishment of
Competent National Authorities could facilitate
equitable access and benefit sharing provisions.
This could have been effectively integrated
into the discussion of access to avian influenza
virus (H5N1) (p 74). Also, there is no
mention of TRIPs Articles 66.2 or 67
(obligating industrialized countries to assist
developing countries in building capacity in
technology transfer and intellectual property
management). Many fascinating topics are
touched upon, yet poorly analyzed.
The reader is left with a book that is
filled with vague finger pointing, advocating
a worn-out development agenda that relies
on funds, trusts, donations, compulsory

licensing, differential pricing and similar aid
mechanisms. This perpetuates the notion
that the hapless South will forever require
assistance, always need to be rescued by
well-meaning intellectuals of the North, and
fosters a failed development agenda that
stresses ‘special’ assistance in lieu of solid,
sustainable global partnerships.
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